Iovance Biotherapeutics

OverviewSuggest Edit

Iovance Biotherapeutics (formerly Lion Biotechnologies) is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes. The Company's lead product candidate is an autologous, ready-to-infuse cell therapy that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. In addition to metastatic melanoma, Lion's TIL technology is potentially applicable to all solid tumors, including ovarian, colorectal, head and neck, and other cancers.

TypePublic
Founded2013
HQSan Carlos, CA, US
Websiteiovance.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Dec 2019)148(+69%)
Job Openings33
Revenue (FY, 2018)$0
Share Price (Nov 2021)$21.1(-10%)
Cybersecurity ratingDMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Iovance Biotherapeutics

Iain Dukes

Iain Dukes

Chairman of the Board
Maria Fardis

Maria Fardis

President & Chief Executive Officer and Director
Ryan Maynard

Ryan Maynard

Director
Frederick G. Vogt

Frederick G. Vogt

General Counsel
Jean-Marc Bellemin

Jean-Marc Bellemin

Chief Financial Officer
Merrill A. McPeak

Merrill A. McPeak

Director
Show more

Iovance Biotherapeutics Office Locations

Iovance Biotherapeutics has offices in San Carlos, New York, Philadelphia and Tampa
San Carlos, CA, US (HQ)
999 Skyway Rd #150
New York, NY, US
112 W 34th St
Philadelphia, PA, US
4747 S Broad St #120
Philadelphia, PA, US
Crescent Dr
Tampa, FL, US
3802 Spectrum Blvd #206
Show all (5)

Iovance Biotherapeutics Financials and Metrics

Iovance Biotherapeutics Revenue

USD

Net income (Q1, 2021)

(75.4m)

EBIT (Q1, 2021)

(75.6m)

Market capitalization (12-Nov-2021)

3.7b

Closing stock price (12-Nov-2021)

21.1

Cash (31-Mar-2021)

132.0m

EV

3.6b
Iovance Biotherapeutics's current market capitalization is $3.7 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

General and administrative expense

12.4m25.6m21.3m28.4m40.8m60.2m

R&D expense

1.8m1.7m1.3m2.7m15.5m28.0m71.6m99.8m166.0m201.7m

Operating expense total

1.8m1.7m1.3m2.7m27.9m53.6m92.9m128.3m206.9m261.9m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

General and administrative expense

2.8m7.3m10.5m4.3m3.9m4.6m7.0m6.8m7.1m9.1m10.9m10.0m13.9m14.4m15.9m19.6m

R&D expense

886.0k270.0k250.0k270.0k250.0k250.0k302.7k361.2k353.9k2.0m4.1m5.0m4.2m4.5m8.5m16.6m19.7m17.8m19.9m24.6m27.9m30.9m39.3m41.6m57.0m49.3m43.1m55.9m

Operating expense total

886.0k270.0k250.0k270.0k250.0k250.0k302.7k361.2k353.9k2.0m4.1m5.0m7.0m11.7m19.0m20.9m23.6m22.3m26.9m31.4m35.1m40.0m50.2m51.6m70.8m63.6m59.0m75.6m
USDQ2, 2011

Financial Leverage

-0.3 x
Show all financial metrics

Iovance Biotherapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

D

69/100

SecurityScorecard logo

Iovance Biotherapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Iovance Biotherapeutics Online and Social Media Presence

Embed Graph

Iovance Biotherapeutics News and Updates

Iovance Biotherapeutics Announces Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapy in Multiple Solid Tumors at Society for Immunotherapy of Cancer (SITC) Annual Meeting

TIL in Combination with Pembrolizumab Increases Overall Responses in Immune-Checkpoint Inhibitor-Naïve Cervical Cancer, Melanoma, and Head and Neck Cancer

Iovance Biotherapeutics to Present Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Cell Therapies Across Multiple Solid Tumors and Treatment Settings at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting

Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune Checkpoint Inhibitor-Naïve Patients with Advanced Cancers

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer

21.4% Overall Response Rate (ORR) in Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer (mNSCLC) Patients Following One or More Prior Systemic Therapies Including Immunotherapy

Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting

Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting

86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study
Show more

Iovance Biotherapeutics Blogs

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Content Import Fri, 11/19/2021 - 17:15 Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) November 19, 2021 at 5:15 PM EST This release i…

Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Cancers at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Tumor Infiltrating Lymphocyte (TIL) Cell Therapy   in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients Shows Overall Response Rate (ORR) of 57% in Cervical Cancer, 60% in Melanoma with 30% Complete Response (CR) and 39% in Head and Neck Cancer SITC Update Conference Call

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society for Immunotherapy of Cancer (SITC) Annual Meeting Content Import Fri, 11/12/2021 - 07:06 Iovance Biotherapeutics Announces Clinical Data for LN-145 in Non-Small Cell Lung Cancer at Society f…

Iovance Biotherapeutics Reports Third Quarter and Year-to-Date 2021 Financial Results and Corporate Updates

Advancing TIL Platform in Multiple Solid Tumors and Treatment Settings SAN CARLOS, Calif. , Nov. 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL,

Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021

Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021 Content Import Mon, 10/25/2021 - 16:02 Iovance Biotherapeutics to Host Third Quarter Financial Results Conference Call and Webcast on Thursday, November 4, 2021 …

Iovance Biotherapeutics to Host Conference Call and Webcast to Highlight Data at Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oral Presentation of Clinical Data for TIL in Combination with Pembrolizumab in Immune-Checkpoint Inhibitor Naïve Patients with Advanced Cancers Poster for TIL Therapy in Advanced, Immune Checkpoint Inhibitor-Treated Non-Small Cell Lung Cancer (NSCLC) SAN CARLOS, Calif. , Oct.
Show more

Iovance Biotherapeutics Frequently Asked Questions

  • When was Iovance Biotherapeutics founded?

    Iovance Biotherapeutics was founded in 2013.

  • Who are Iovance Biotherapeutics key executives?

    Iovance Biotherapeutics's key executives are Iain Dukes, Maria Fardis and Ryan Maynard.

  • How many employees does Iovance Biotherapeutics have?

    Iovance Biotherapeutics has 148 employees.

  • Who are Iovance Biotherapeutics competitors?

    Competitors of Iovance Biotherapeutics include Achilles Therapeutics, Gracell and Heidelberg Pharma.

  • Where is Iovance Biotherapeutics headquarters?

    Iovance Biotherapeutics headquarters is located at 999 Skyway Rd #150, San Carlos.

  • Where are Iovance Biotherapeutics offices?

    Iovance Biotherapeutics has offices in San Carlos, New York, Philadelphia and Tampa.

  • How many offices does Iovance Biotherapeutics have?

    Iovance Biotherapeutics has 5 offices.